Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis
IntroductionCombinations of immune checkpoint inhibitors (ICIs) and angiogenesis inhibitors (AIs) have been investigated for the treatment of several tumor types. Both ICIs and AIs may lead to cardiovascular adverse events, and their combination may potentially increase the risk for cardiovascular t...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2024-02-01
|
| Серія: | Frontiers in Cardiovascular Medicine |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1309100/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
